SynthesisInfectious diseases of poverty2021
Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Infectious diseases of poverty, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 11 syntheses or guidelines pooled it.
- Safety and Effectiveness of COVID-19 Vaccines During Pregnancy: A Living Systematic Review and Meta-analysis.Drug safety · 2024Pooled it
- Pooled it
- A systematic review and meta-analysis of the global prevalence and determinants of COVID-19 vaccine acceptance and uptake in people living with HIV.Nature human behaviour · 2024Pooled it
- Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2-18 years: an updated systematic review and meta-analysis.World journal of pediatrics : WJP · 2023Pooled it
- Effectiveness and Safety of COVID-19 Vaccinations: An Umbrella Meta-Analysis.International journal of public health · 2023Pooled it
- Humoral and cellular response of COVID-19 vaccine among solid organ transplant recipients: A systematic review and meta-analysis.Transplant infectious disease : an official journal of the Transplantation Society · 2022Pooled it
- The immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy individuals: A systematic review and meta-analysis.Transplant immunology · 2022Pooled it
- COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis.Clinical and molecular hepatology · 2022Pooled it
- Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials.Journal of medical virology · 2022Pooled it
- Adverse events following COVID-19 vaccination: A systematic review and meta-analysis.International immunopharmacology · 2022Pooled it
- Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.Infectious diseases of poverty · 2021Pooled it
- Colorectal cancer and tumor vaccines (Review).Oncology letters · 2026Review
- The immunogenicity and safety of adenoviral-based vaccines.Current opinion in allergy and clinical immunology · 2026Review
- Vaccination burnout impedes the compliance with multiple-dose administration of vaccines.Scientific reports · 2025Article
- Self-Reported Adverse Events Following COVID-19 Vaccination Among Medical Sciences Students After a Symptomatology Training Program: A Cross-Sectional Study.Health science reports · 2025Article
- Serious adverse events following immunization and predictors of mortality associated with COVID-19 vaccination in India: a secondary data analysis of nationwide causality assessments.Therapeutic advances in vaccines and immunotherapy · 2025Article
- The complexities of 'trust' in the context of COVID-19 vaccination choices among Black women in Alameda County, CA.Critical public health · 2025Article
- Evaluating the safety profile of the CoronaVac in adult and older adult populations: A phase IV prospective observational study in Brazil.PLOS global public health · 2025Article
- Realizing time-staggered expression of nucleic acid-encoded proteins by co-delivery of messenger RNA and plasmid DNA on a single nanocarrier.Drug delivery and translational research · 2024Article
- Predictors of moderate-to-severe side-effects following COVID-19 mRNA booster vaccination: a prospective cohort study among primary health care providers in Belgium.BMC infectious diseases · 2024Observational
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundVarious modalities of vaccines against coronavirus disease 2019 (COVID-19), based on different platforms and immunization procedures, have been successively approved for marketing worldwide. A comprehensive review for clinical trials assessing the safety of COVID-19 vaccines is urgently needed to make an accurate judgment for mass vaccination. MAIN TEXT: A systematic review and meta-analysis was conducted to determine the safety of COVID-19 vaccine candidates in randomized controlled trials (RCTs). Data search was performed in PubMed, Embase, Cochrane library, Scopus, Web of Science, and MedRxiv. Included articles were limited to RCTs on COVID-19 vaccines. A total of 73,633 subjects from 14 articles were included to compare the risks of adverse events following immunization (AEFI) after vaccinating different COVID-19 vaccines. Pooled risk ratios (RR) of total AEFI for inactivated vaccine, viral-vectored vaccine, and mRNA vaccine were 1.34 [95% confidence interval (CI) 1.11-1.61, P < 0.001], 1.65 (95% CI 1.31-2.07, P < 0.001), and 2.01 (95% CI 1.78-2.26, P < 0.001), respectively. No significant differences on local and systemic AEFI were found between the first dose and second dose. In addition, people aged ≤ 55 years were at significantly higher risk of AEFI than people aged ≥ 56 years, with a pooled RR of 1.25 (95% CI 1.15-1.35, P < 0.001).
conclusionsThe safety and tolerance of current COVID-19 vaccine candidates are acceptable for mass vaccination, with inactivated COVID-19 vaccines candidates having the lowest reported AEFI. Long-term surveillance of vaccine safety is required, especially among elderly people with underlying medical conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.